The complete official prescribing information should be consulted for authoritative instructions. The following is a summary of the current U.S. Rezdiffra label revised December 2025.
Indication
Rezdiffra is indicated with diet and exercise for adults with noncirrhotic NASH with moderate to advanced liver fibrosis consistent with F2–F3 fibrosis.
Dosage
- Less than 100 kg: 80 mg once daily.
- 100 kg or more: 100 mg once daily.
Dosage forms
Rezdiffra is available as 60 mg, 80 mg and 100 mg tablets.
Contraindications
The current U.S. label lists no contraindications.
Major warnings and precautions
The label addresses:
- Hepatotoxicity
- Gallbladder-related adverse reactions
- Interactions with certain statins
- CYP2C8-mediated interactions
- Hepatic impairment
Adverse reactions
Common adverse reactions include diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain and dizziness.
Complete label
This summary does not replace the official prescribing information. The latest regulatory label applicable to the patient’s jurisdiction should always be consulted.
Resiliva limitation
Resiliva-specific prescribing information is Everest Pharmaceuticals Ltd. The information above describes the FDA-approved reference product rather than asserting that Resiliva has identical authorization.